… by year end 2021 Initial clinical data from Phase 1/2 Aurora trial of QR-1123 for autosomal dominant retinitis … the fifth single dose cohort of patients in the Phase 1/2 Aurora trial for adRP with initial clinical data (n=11) expected in Q4. Aurora is a first-in-human clinical study, designed to …
… anticipates sharing initial findings from the Phase 1 Aurora trial of QR-1123 for autosomal dominant retinitis pigmentosa (adRP) in Q4. Aurora is a first-in-human clinical study, designed to … About QR-1123 QR-1123 is being evaluated in the Phase 1/2 Aurora trial and is a first-in-class investigational RNA …
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension st
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;
Strategic convertible debt financing extends runway into 2023 if fully draw
… and Program Updates Sepofarsen for Leber congenital amaurosis 10 (LCA10): In April, the first patient was dosed … data from the single dose cohorts (n=8) of the Phase 1/2 Aurora trial in 2021. QR-504a for Fuchs Endothelial Corneal … About QR-1123 QR-1123 is being evaluated in the Phase 1/2 Aurora trial and is a first-in-class investigational RNA …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in